Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Top OTC Stories 2013: Switch, Consumer Business Divestment Plans

This article was originally published in The Tan Sheet

Executive Summary

The most-read OTC sector stories in “The Tan Sheet” during 2013 include Sanofi’s switch of Nasacort AQ 24HR, an interview with the former director of FDA’s Division of Nonprescription Clinical Evaluation, and Merck and Novartis each pondering the sale of its consumer health unit.

You may also be interested in...



“Likely” Merck Consumer Health Sale Could Bring $8 Billion – Analysts

Merck executives shift their position about the potential divestiture of its non-pharma assets, including the consumer health business. J.P. Morgan analysts expect a sale of the consumer unit, and say Merck’s brands including Claritin and Coppertone could grow globally with a new owner.

Sanofi Sues FDA To Stop Publication Of Nasacort Labeling Before Launch

After FDA denied Sanofi three years of market exclusivity for OTC Nasacort, the firm filed suit against the agency not to publish the product’s labeling prior to the launch. If successful, the firm could postpone the launch of generic competition.

Sanofi’s Nasacort First-In-Class Switch Receives FDA Approval

The firm’s Chattem division will bring the 24-hour nasal allergy spray to market in the spring of 2014.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106770

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel